Pure Global
NCT04809623

Study of GS-5718 in Participants With Cutaneous Lupus Erythematosus (CLE)

A Randomized, Blinded, Placebo-Controlled, Phase 1b Study of GS-5718 in Subjects With Cutaneous Lupus Erythematosus (CLE)
Gilead Sciences·Phase 1·ClinicalTrials.gov·drugSuspended
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Cutaneous Lupus Erythematosus
Drug/Device/Intervention
GS-5718
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Gilead Sciences
Location
Beverly Hills,Clearwater,Indianapolis,Charlotte,Dallas, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Sep 01, 2021
End date
Jan 01, 2023
Enrollment
12 participants
Primary outcome

Percentage of Participants Experiencing Adverse Events,Percentage of Participants Experiencing Laboratory Abnormalities

Summary

The primary objective of this study is to evaluate the safety and tolerability of GS-5718 in
 participants with Cutaneous Lupus Erythematosus (CLE) with or without Systemic Lupus
 Erythematosus (SLE).

ICD-10 classifications
Subacute cutaneous lupus erythematosusLupus erythematosusDiscoid lupus erythematosusSystemic lupus erythematosusSystemic lupus erythematosus, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04809623
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04809623 through Pure Global AI's free database. This Phase 1 trial is sponsored by Gilead Sciences and is currently Suspended. The study focuses on Cutaneous Lupus Erythematosus. Target enrollment is 12 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.